Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
BackgroundLenalidomide is a thalidomide analog that has immunomodulatory and anti-angiogenic properties. The ECOC-ACRIN E1412 Phase II trial demonstrated that lenalidomide, when combined with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), extended survival in diffuse...
Saved in:
| Main Authors: | Rongqi Li, Yuhan Zeng, Yizhang Chen, Zhongjiang Ye, Chuang Chen, Jianhui Yang, Jing Fu, Tao Zhou, Danna Jiang, Sunting Qin, Haige Ye, Ziye Zhou, Xiuhua Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1412743/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of CHOP‐19 and CHOP‐25 for treatment of peripheral nodal B‐cell lymphoma in dogs: A European multicenter retrospective cohort study
by: Charles Hawkes, et al.
Published: (2024-11-01) -
Prediction model of male reproductive function damage caused by CHOP chemotherapy regimen for non-Hodgkin's lymphoma
by: Jiabao Zhang, et al.
Published: (2024-11-01) -
Screening of Probiotics Derived from Chopped Chili and Its Application in Fermented Chopped Chili
by: Qian YANG, et al.
Published: (2025-02-01) -
Prototype of the chopping machine for the fronds and leaves of oil palms
by: Bayu Susilo, et al.
Published: (2023-06-01) -
Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway
by: Qian Wang, et al.
Published: (2025-01-01)